Original Article

You have full text access to this OnlineOpen article

The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module

EORTC QLQ-CX24†

  1. Elfriede R. Greimel PhD1,‡,*,
  2. Karin Kuljanic Vlasic MA2,
  3. Ann-Charlotte Waldenstrom MD3,
  4. Vlatka M. Duric PhD4,
  5. Pernille T. Jensen MD, PhD5,
  6. Susanne Singer PhD6,
  7. Weichu Chie MD, PhD7,
  8. Andy Nordin MBBS8,
  9. Vesna Bjelic Radisic MD1,
  10. Dariusz Wydra MD, PhD9,
  11. on behalf of the European Organization for Research and Treatment of Cancer Quality-of-Life Group§

Article first published online: 14 SEP 2006

DOI: 10.1002/cncr.22217

Issue

Cancer

Cancer

Volume 107, Issue 8, pages 1812–1822, 15 October 2006

Additional Information

How to Cite

Greimel, E. R., Kuljanic Vlasic, K., Waldenstrom, A.-C., Duric, V. M., Jensen, P. T., Singer, S., Chie, W., Nordin, A., Bjelic Radisic, V., Wydra, D. and on behalf of the European Organization for Research and Treatment of Cancer Quality-of-Life Group (2006), The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module. Cancer, 107: 1812–1822. doi: 10.1002/cncr.22217

Author Information

  1. 1

    Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria

  2. 2

    Department of Gynecology and Obstetrics, University Hospital Center Rijeka, Rijeka, Croatia

  3. 3

    Department of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden

  4. 4

    National Health and Medical Research Council Clinical Trials Centre, University of Sydney and Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, New South Wales, Australia

  5. 5

    Department of Obstetrics and Gynecology, Herlev University Hospital, Copenhagen, Denmark

  6. 6

    Department of Social Medicine, University of Leipzig, Leipzig, Germany

  7. 7

    Department of Public Health and Institute of Preventative Medicine, National Taiwan University, Taipei, Taiwan

  8. 8

    East Kent Gynaecological Oncology Centre, Queen Elizabeth the Queen Mother Hospital, Margate, United Kingdom

  9. 9

    Department of Gynecology, Medical University of Gdansk, Gdansk, Poland

  1. ‡

    Fax: 011 (43) 3163853061.

  2. §

    The following are members of the EORTC Gynecological Cancer Group Steering Committee: K. Bergmark (Sweden), C. Creutzberg (the Netherlands), B. DeSouza (Brazil), F. Fehlauer (Germany), L. Incrocci (The Netherlands), J. Routledge (U.K.), T. Swift (U.K.), and H. Y. Yun (Korea).

*Department of Obstetrics and Gynecology, Medical University Graz, Auenbruggerplatz 14, 8036 Graz, Austria

  1. †

    The EORTC QLQ-CX24 is copyrighted by the EORTC QoL Group. The module and the scoring procedure are available on request (Andrew Bottomley, PhD, EORTC Quality of Life Unit; E-mail: abo@eortc.be).

Publication History

  1. Issue published online: 3 OCT 2006
  2. Article first published online: 14 SEP 2006
  3. Manuscript Accepted: 27 JUL 2006
  4. Manuscript Revised: 25 JUL 2006
  5. Manuscript Received: 5 APR 2006

Funded by

  • European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Group
  • National Science Council, Taiwan. Grant Number: (NSC 93-2320-B0002-072, NSC 94-2314-B-00 2-098)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (132K)

REFERENCES

  • 1
    Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J. 2003; 9: 348–359.
  • 2
    Gusberg SB, Runowiczl CD. Gynecologic cancers. In: HollebAI, FinkDJ, MurphyGP, editors. Textbook of Clinical Oncology. Atlanta: American Cancer Society, 1991; 481–485.
  • 3
    Keys H, Gibbons SK. Optimal management of locally advanced cervical carcinoma. J Natl Cancer Inst Monogr. 1996; 89–92.
  • 4
    Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001; 385: 781–786.
  • 5
    Buda A, Fossati R, Colombo N, et al. Randomized trail of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol. 2005; 23: 4137–4146.
  • 6
    Long HJ3rdI, Bundy BN, Grendys ECJr., et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005; 23: 4626–4633.
  • 7
    Monk BJ, Huang HQ, Cella D, et al. Quality of life outcomes from a randomized Phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005; 23: 1–7.
  • 8
    Aaronson NK, Ahmedzai S, Bergman B, et al., for the EORTC Study Group on Quality of Life. The EORTC QLQ-C30. A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365–375.
  • 9
    Sprangers MAG, Cull A, Groenvold M, et al. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. Qual Life Res. 1998; 7: 291–300.
  • 10
    Blazeby J, Sprangers M, Cull A, et al. EORTC Quality of Life Group Guidelines for Developing Questionnaire Modules. 3rd ed. Brussels: EORTC Publications; 2001.
  • 11
    Cull A, Sprangers M, Bjordal K, et al. EORTC Quality of Life Group Translation Procedure. 2nd ed. Brussels: EORTC Publications; 2002.
  • 12
    Schwab DP. Construct validity in organization behavior. In: StawBM, CummingsLL, editors. Research in Organizational Behaviour. Greenwich: JAI Press, 1980: 3–43.
  • 13
    Fayers PM, Machin D. Multi-item scales. In: FayersPM, MachinD, editors. Quality of Life. Assessment, Analysis and Interpretation. West Sussex: John Wiley & Sons Ltd.; 2000: 72–90.
  • 14
    Cohen J. Statistical Power Analysis for the Behavioral Sciences, revised ed. New York: Academic Press; 1977.
  • 15
    Calhoun EA, Fishman DA, Lurain JR, et al. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol. 2004; 93: 164–169.
  • 16
    Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO Stage 1B carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1995; 32: 1289–1300.
  • 17
    Portenoy RK, Thaler H, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994; 30A: 1326–1336.
  • 18
    Steineck G, Bergmark K, Henningsohn L, et al. Symptom documentation in cancer survivors as a basis for therapy modifications. Acta Oncol. 2002; 41: 244–252.
  • 19
    Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: EORTC Publications; 2001.
View Full Article (HTML) Get PDF (132K)